Protagonist Therapeutics (PTGX)

Protagonist Therapeutics Stock Analysis & Ratings

PTGX Stock Chart & Stats

Day’s Range$7.69 - $8.04
52-Week Range$7.49 - $50.54
Previous Close$7.85
Average Volume (3M)1.04M
Market Cap$384.87M
P/E Ratio-3.0
Next EarningsAug 09, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score4
EPS (TTM)-2.59



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Protagonist Therapeutics’s price range in the past 12 months?
Protagonist Therapeutics lowest stock price was $7.49 and its highest was $50.54 in the past 12 months.
    What is Protagonist Therapeutics’s market cap?
    Protagonist Therapeutics’s market cap is $384.87M.
      What is Protagonist Therapeutics’s price target?
      The average price target for Protagonist Therapeutics is $45.00. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $50.00 ,the lowest forecast is $40.00. The average price target represents 468.90% Increase from the current price of $7.91.
        What do analysts say about Protagonist Therapeutics?
        Protagonist Therapeutics’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
          When is Protagonist Therapeutics’s upcoming earnings report date?
          Protagonist Therapeutics’s upcoming earnings report date is Aug 09, 2022 which is in 82 days.
            How were Protagonist Therapeutics’s earnings last quarter?
            Protagonist Therapeutics released its earnings results on May 04, 2022. The company reported -$0.43 earnings per share for the quarter, beating the consensus estimate of -$0.54 by $0.11.
              Is Protagonist Therapeutics overvalued?
              According to Wall Street analysts Protagonist Therapeutics’s price is currently Undervalued.
                Does Protagonist Therapeutics pay dividends?
                Protagonist Therapeutics does not currently pay dividends.
                What is Protagonist Therapeutics’s EPS estimate?
                Protagonist Therapeutics’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Protagonist Therapeutics have?
                Protagonist Therapeutics has 48,660,000 shares outstanding.
                  What happened to Protagonist Therapeutics’s price movement after its last earnings report?
                  Protagonist Therapeutics reported an EPS of -$0.43 in its last earnings report, beating expectations of -$0.54. Following the earnings report the stock price went down -0.204%.
                    Which hedge fund is a major shareholder of Protagonist Therapeutics?
                    Among the largest hedge funds holding Protagonist Therapeutics’s share is Farallon Capital Management, L.L.C.. It holds Protagonist Therapeutics’s shares valued at 27M.


                      Protagonist Therapeutics Stock Analysis

                      The Protagonist Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Protagonist Therapeutics

                      Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. The firm's initial lead product candidates, PTG-100 and PTG-200, are being developed for moderate-to-severe ulcerative colitis and Crohn's disease, respectively. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

                      Similar Stocks
                      Price & Change
                      Seres Therapeutics
                      Nektar Therapeutics
                      Gilead Sciences

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis